LoRusso PM et al. |
Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. |
2011 |
Clin. Cancer Res. |
pmid:22003071
|
Blanc V et al. |
SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. |
2011 |
Clin. Cancer Res. |
pmid:22003072
|
Bertholjotti I |
[Antibody-drug conjugate--a new age for personalized cancer treatment]. |
2011 |
Chimia (Aarau) |
pmid:22026193
|
Gurtner K et al. |
Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo. |
2012 |
Radiother Oncol |
pmid:22100655
|
Bai RL et al. |
Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. |
1990 |
J. Biol. Chem. |
pmid:2211617
|
Eichner S et al. |
The interplay between mutasynthesis and semisynthesis: generation and evaluation of an ansamitocin library. |
2012 |
Angew. Chem. Int. Ed. Engl. |
pmid:22135226
|
Taft F et al. |
Combined muta- and semisynthesis: a powerful synthetic hybrid approach to access target specific antitumor agents based on ansamitocin P3. |
2012 |
Chemistry |
pmid:22170289
|
Kang Q et al. |
Biosynthesis of 3,5-AHBA-derived natural products. |
2012 |
Nat Prod Rep |
pmid:22193711
|
Li Y et al. |
Dual carbamoylations on the polyketide and glycosyl moiety by asm21 result in extended ansamitocin biosynthesis. |
2011 |
Chem. Biol. |
pmid:22195559
|
Knobloch T et al. |
Mutational biosynthesis of ansamitocin antibiotics: a diversity-oriented approach to exploit biosynthetic flexibility. |
2011 |
Chembiochem |
pmid:22238146
|
Shen BQ et al. |
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. |
2012 |
Nat. Biotechnol. |
pmid:22267010
|
Girish S et al. |
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. |
2012 |
Cancer Chemother. Pharmacol. |
pmid:22271209
|
Segraves NL et al. |
An isolable acyclic hemiacetal of ansamitocin P-3. |
2012 |
Magn Reson Chem |
pmid:22374862
|
Erickson HK et al. |
The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. |
2012 |
Mol. Cancer Ther. |
pmid:22408268
|
Aldrich CD |
Pleiotropic phenotype of cultured murine cells resistant to maytansine, vincristine, colchicine, and adriamycin. |
1979 |
J. Natl. Cancer Inst. |
pmid:224236
|
Lu D et al. |
Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer. |
2012 |
Curr. Drug Metab. |
pmid:22475266
|
Shen BQ et al. |
Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. |
2012 |
Curr. Drug Metab. |
pmid:22475269
|
Beeram M et al. |
A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. |
2012 |
Cancer |
pmid:22648179
|
Krop IE et al. |
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. |
2012 |
J. Clin. Oncol. |
pmid:22649126
|
Thon JN et al. |
High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production. |
2012 |
Blood |
pmid:22665936
|